Psychosis Risk In 22Q11.2 Deletion Syndrome: Findings From The Philadelphia Sample
Sign Up to like & getrecommendations! Published in 2017 at "European Neuropsychopharmacology"
DOI: 10.1016/j.euroneuro.2016.09.566
Abstract: Abstract Aim Schizophrenia research emphasizes identification of people at risk of psychosis. 22q11DS, associated with increased risk for schizophrenia, is a window for studying emerging psychosis. Such efforts require systematic evaluation of subthreshold psychotic symptoms… read more here.
Keywords: subthreshold psychotic; risk; psychosis; youths 22q11ds ... See more keywords
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Sign Up to like & getrecommendations! Published in 2017 at "The Lancet"
DOI: 10.1016/s0140-6736(17)31442-3
Abstract: BACKGROUND The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of… read more here.
Keywords: anaplastic glioma; deleted anaplastic; adjuvant temozolomide; concurrent ... See more keywords